HGF has one of the largest and most experienced pharmaceutical patent attorney/lawyer teams in Europe. Many of our attorneys and solicitors have joined from large pharmaceutical companies and bring extensive in-house experience of building, managing enforcing and defending global patent portfolios protecting some of the highest profile medicines in Europe.
Our multidisciplinary team supports clients through all stages of the development and lifespan of a pharmaceutical product. We specialise in providing IP strategy advice, invention capture, drafting and filing patent applications, patent prosecution, infringement analysis, EPO oppositions/appeals, commercialisation across the life cycle and multi-jurisdictional patent litigation. We also have specialist experience of supplementary protection certificates (SPCs), regulatory data exclusivity and IP due diligence. A large part of our pharmaceutical practice involves contentious proceedings in the courts and at the EPO. A number of our experienced patent attorneys specialise in opposition and appeal proceedings before the European Patent Office and are regularly involved with complex and high-value multi-party oppositions. Our team of solicitors, working together with our patent attorneys, are also regularly involved in high-profile pharmaceutical patent disputes i nthe national Courts and across Europe.
In terms of technical expertise, our multidisciplinary team specialises in IP relating to drug compounds, particular forms of drug compounds (salt, solvates and polymorphs), formulations (including advanced drug delivery systems), processes for making drug compounds, methods of treatment and therapeutic uses (including drug repositioning), dosage regimens, combination therapies, drug conjugates (such as antibody drug conjugates and PROTACs) and neutraceuticals.
We’ve built our business by recruiting and developing specialists, not generalists. When it comes to protecting your ideas and business, you want to know you’re working with the best – people who truly understand your sector and the potential of your IP.
HGF’s team has pharmaceuticals professionals from an array of academic and business backgrounds. Our team-based approach ensures our clients benefit from the very best strategic advice from people who understand not only the legal environment but also the practical side of your business.
We are delighted to announce that 9 of our team have been promoted to director effective from today, 1 December 2023. These promotions are effective from today, 1 December 2023 …Read article
A patent is a legal right that enables the patent holder to prevent others from making and using their invention in the country where the patent is granted. To many …Read article
“Please amend to fall into line with the granted claims in the US” is a phrase generally received with caution from attorneys practicing in non-US jurisdictions. The principle cause for …Event details
A recent decision by the UK High Court has delivered a highly favourable verdict for AI innovators, which could change the way that the patentability of AI-related inventions is assessed …Read article
HGF announced a new Chair to its Management Board, Lucy Johnson. Lucy was previously head of the firm’s Engineering Group. Effective immediately Lucy succeeds Jason Lumber who held the position …Read article
Safeguard measure: Excess page fees on ST.25 sequence listings included as part of a divisional application to be waived by the EPO. Following the implementation of WIPO Sequence standard ST.26, …Read article